Arcellx, Inc.
ACLX
株式のランク
#2789
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
株価
$115.07
最終同期: 2026-05-15
時価総額
$6.73B
変化（1日）
0.00%
変化（1年）
34.40%
国
US
取引 Arcellx, Inc. (ACLX)
カテゴリー
Healthcare
Arcellx, Inc.（ACLX）の収益
Dec 2025 時点の収益 TTM: $22.29M
Arcellx, Inc. の最新の財務報告によると、現在の収益 (TTM) は $22.29M です。2023 年には $110.32M の収益があり、これは 2022 年の 0.00 と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Arcellx, Inc. の収益履歴（2018 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $22.29M | -79.35% |
| 2024 | $107.94M | -2.16% |
| 2023 | $110.32M | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $12.62B | 56,546.77% |
US
|
|
| $2.23B | 9,897.31% |
US
|
|
| $15.74B | 70,546.72% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 26,918.25% |
NL
|
